3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lymphoma
149
Lymphoma, Large B-Cell, Diffuse
114
Lymphoma, Non-Hodgkin
110
Precursor Cell Lymphoblastic Leukemia-Lymphoma
106
Leukemia
81
Hodgkin Disease
81
Small Cell Lung Carcinoma
79
Leukemia, Myeloid, Acute
73
Burkitt Lymphoma
69
Lymphoma, Follicular
67
Lymphoma, Mantle-Cell
65
Lung Neoplasms
60
Lymphoma, Large-Cell, Immunoblastic
54
Leukemia, Lymphocytic, Chronic, B-Cell
47
Recurrence
40
Multiple Myeloma
39
Lymphoma, B-Cell, Marginal Zone
36
Neuroblastoma
33
Congenital Abnormalities
29
Carcinoma, Non-Small-Cell Lung
28
Lymphoma, B-Cell
25
Myelodysplastic Syndromes
24
Lymphoma, Large-Cell, Anaplastic
23
Lymphoma, Extranodal NK-T-Cell
23
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
22
Brain Neoplasms
22
Sarcoma
21
Ovarian Neoplasms
21
Lymphoma, T-Cell, Peripheral
20
Central Nervous System Neoplasms
20
Interventions
Cyclophosphamide
10
fludarabine
5
Radiotherapy
5
Doxorubicin
5
Gemcitabine
3
sargramostim
2
fludarabine phosphate
2
aldesleukin
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Leukapheresis
2
Ifosfamide
2
Docetaxel
2
Decitabine
2
Dacarbazine
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
trofosfamide
1
tremelimumab
1
temsirolimus
1
sotigalimab
1
ribociclib
1
poly ICLC
1
pembrolizumab
1
pegfilgrastim
1
pazopanib
1
pasireotide
1
olaparib
1
lutetium Lu 177 dotatate
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sarcoma, Synovial
×
Etoposide
×
Clear all
NCT00876031
2022-11-08
CWS-2007-HR
University Hospital Tuebingen
Phase 3
Completed
195 enrolled